2002
DOI: 10.1016/s0300-2896(02)75272-1
|View full text |Cite
|
Sign up to set email alerts
|

Toxicidad pulmonar por talidomida

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
3
0

Year Published

2003
2003
2023
2023

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 27 publications
(4 citation statements)
references
References 25 publications
0
3
0
Order By: Relevance
“…A case report described a pattern of right-side heart failure and concomitant dyspnea, with features of interstitial pneumonia on a chest X-ray [7]. On discontinuing the thalidomide, this patient's symptoms improved; however, because no chest CT or bronchoscopic findings were described in this case, it could not be concluded that the pulmonary side effects were definitely caused by thalidomide.…”
Section: Discussionmentioning
confidence: 91%
“…A case report described a pattern of right-side heart failure and concomitant dyspnea, with features of interstitial pneumonia on a chest X-ray [7]. On discontinuing the thalidomide, this patient's symptoms improved; however, because no chest CT or bronchoscopic findings were described in this case, it could not be concluded that the pulmonary side effects were definitely caused by thalidomide.…”
Section: Discussionmentioning
confidence: 91%
“…Patients present with fever and asthma like symptoms which progress to respiratory failure and pulmonary infiltrates (98). There have also been reports of lung toxicity following Thalidomide (99) and Lenalidomide(100) with toxic granulomatous interstitial pulmonary disease which is steroid responsive.…”
Section: Systemic Al Amyloidosismentioning
confidence: 99%
“…Adverse events (typically constipation, dizziness or malaise) were, however, reported in 74% of patients receiving thalidomide compared with 22% receiving placebo. These findings suggest that thalidomide may be an effective therapy for symptomatic treatment of chronic cough in patients with IPF; however, this was a small single-centre trial and thalidomide has been associated with the development of acute interstitial lung processes [65,66,67,68] and thromboembolic events [69]. Further multi-centre studies are therefore essential to confirm both safety and efficacy of thalidomide in the treatment of chronic cough in IPF.…”
Section: Recent Significant Clinical Trials (2010 Onwards)mentioning
confidence: 99%